Study on Partial Enteral Nutrition Augmenting Therapy in Active Crohn's Disease
A multicenter trial is investigating the efficacy of partial enteral nutrition combined with pharmacologic therapy in Crohn's disease.
Phase III
Crohn's disease therapies
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing trial on partial enteral nutrition (PEN) as an adjunct therapy for Crohn's disease could significantly alter treatment paradigms if proven effective. This may lead to changes in clinical guidelines and influence the competitive landscape for existing therapies in gastroenterology.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor recruitment progress and interim results for efficacy and tolerability of the combination therapy.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.